# CheckMate 77T (NCT04025879)

> A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04025879
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Bristol-Myers Squibb
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Nivolumab; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed; Placebo; Docetaxel
- Enrollment: 461
- Primary outcome: Event-Free Survival (EFS) by BICR

## Questions raised in the commentary

_Automated from the 40 newest of 276 indexed sources (Jul 2025 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether adjuvant nivolumab adds benefit beyond neoadjuvant treatment
- Whether ctDNA can guide postoperative immunotherapy decisions
- How to manage patients without a pathologic complete response

## Indexed commentary on CheckMate 77T so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 144
- YouTube: 64
- Podcasts: 50
- Bluesky threads: 16
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=checkmate-77t-nct04025879

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04025879", "email": "<work email>"}; the inbox owner confirms by the emailed link.